Gene specific effects on brain volume and cognition of <i>TMEM106B</i> in frontotemporal lobar degeneration.

ABSTRACT:

Background and objectives

TMEM106B has been proposed as a modifier of disease risk in FTLD-TDP, particularly in GRN mutation carriers. Furthermore, TMEM106B has been investigated as a disease modifier in the context of healthy aging and across multiple neurodegenerative diseases. The objective of this study is to evaluate and compare the effect of TMEM106B on gray matter volume and cognition in each of the common genetic FTD groups and in sporadic FTD patients.

Methods

Participants were enrolled through the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study, which includes symptomatic and presymptomatic individuals with a pathogenic mutation in C9orf72, GRN, MAPT, VCP, TBK1, TARDBP, symptomatic non-mutation carriers

SUBMITTER: Vandebergh M 

PROVIDER: S-EPMC11023674 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature